JP2011517654A5 - - Google Patents

Download PDF

Info

Publication number
JP2011517654A5
JP2011517654A5 JP2010524829A JP2010524829A JP2011517654A5 JP 2011517654 A5 JP2011517654 A5 JP 2011517654A5 JP 2010524829 A JP2010524829 A JP 2010524829A JP 2010524829 A JP2010524829 A JP 2010524829A JP 2011517654 A5 JP2011517654 A5 JP 2011517654A5
Authority
JP
Japan
Prior art keywords
patent document
pat
application publication
patent application
document
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010524829A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011517654A (ja
JP5730572B2 (ja
Filing date
Publication date
Priority claimed from US11/900,851 external-priority patent/US20080069891A1/en
Priority claimed from US12/075,543 external-priority patent/US8445018B2/en
Application filed filed Critical
Priority claimed from PCT/US2008/003598 external-priority patent/WO2009035474A1/en
Publication of JP2011517654A publication Critical patent/JP2011517654A/ja
Publication of JP2011517654A5 publication Critical patent/JP2011517654A5/ja
Application granted granted Critical
Publication of JP5730572B2 publication Critical patent/JP5730572B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010524829A 2007-09-13 2008-03-19 濫用抵抗性製剤 Active JP5730572B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US11/900,851 US20080069891A1 (en) 2006-09-15 2007-09-13 Abuse resistant drug formulation
US11/900,851 2007-09-13
USPCT/US2007/020041 2007-09-14
PCT/US2007/020041 WO2008033523A1 (en) 2006-09-15 2007-09-14 Abuse resistant drug formulation
US12/075,543 2008-03-12
US12/075,543 US8445018B2 (en) 2006-09-15 2008-03-12 Abuse resistant drug formulation
PCT/US2008/003598 WO2009035474A1 (en) 2007-09-13 2008-03-19 Abuse resistant drug formulation

Publications (3)

Publication Number Publication Date
JP2011517654A JP2011517654A (ja) 2011-06-16
JP2011517654A5 true JP2011517654A5 (cg-RX-API-DMAC7.html) 2012-06-07
JP5730572B2 JP5730572B2 (ja) 2015-06-10

Family

ID=39493594

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010524829A Active JP5730572B2 (ja) 2007-09-13 2008-03-19 濫用抵抗性製剤

Country Status (9)

Country Link
EP (1) EP2200593B1 (cg-RX-API-DMAC7.html)
JP (1) JP5730572B2 (cg-RX-API-DMAC7.html)
CA (1) CA2699142C (cg-RX-API-DMAC7.html)
DK (1) DK2200593T5 (cg-RX-API-DMAC7.html)
ES (1) ES2611794T3 (cg-RX-API-DMAC7.html)
HU (1) HUE032012T2 (cg-RX-API-DMAC7.html)
MX (1) MX336861B (cg-RX-API-DMAC7.html)
PL (1) PL2200593T3 (cg-RX-API-DMAC7.html)
WO (1) WO2009035474A1 (cg-RX-API-DMAC7.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
WO2003024429A1 (en) 2001-09-21 2003-03-27 Egalet A/S Polymer release system
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US8877241B2 (en) 2003-03-26 2014-11-04 Egalet Ltd. Morphine controlled release system
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
TWI454288B (zh) 2008-01-25 2014-10-01 Gruenenthal Chemie 藥物劑型
ES2599031T3 (es) 2008-05-09 2017-01-31 Grünenthal GmbH Proceso para la preparación de una formulación de polvo intermedia y una forma de dosificación solida final utilizando un paso de congelación por pulverización
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
AU2010265213B2 (en) 2009-06-24 2012-08-23 Egalet Ltd. Controlled release formulations
ES2534908T3 (es) 2009-07-22 2015-04-30 Grünenthal GmbH Forma de dosificación de liberación controlada extruida por fusión en caliente
BR112012001466A2 (pt) 2009-07-22 2020-08-11 Grünenthal GmbH forma de dosagem resistente à falsificação para opioides sensíveis à oxidação, seu processo de fabricação, e embalagem
CA2784407A1 (en) * 2009-12-17 2011-07-14 Cima Labs Inc. Abuse-resistant formulations
US20110150989A1 (en) * 2009-12-22 2011-06-23 Mallinkckrodt Inc. Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
ES2628886T3 (es) * 2010-02-24 2017-08-04 Cima Labs Inc. Formulaciones resistentes al abuso
EP2568977A1 (en) * 2010-05-11 2013-03-20 Cima Labs Inc. Alcohol-resistant metoprolol-containing extended- release oral dosage forms
WO2011143119A1 (en) * 2010-05-11 2011-11-17 Cima Labs Inc. Alcohol-resistant extended release dosage forms comprising venlafaxine
AU2011253216B2 (en) * 2010-05-11 2016-10-20 Cima Labs Inc. Alcohol-resistant formulations
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
WO2012028318A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
BR112014002022A2 (pt) 2011-07-29 2017-02-21 Gruenenthal Gmbh comprimido resistente à violação proporcionando liberação de fármaco imediata
JP6063462B2 (ja) 2011-07-29 2017-01-18 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 即時薬剤放出を提供するタンパーレジスタント錠剤
BR112014019988A8 (pt) 2012-02-28 2017-07-11 Gruenenthal Gmbh Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico
LT2838512T (lt) 2012-04-18 2018-11-12 Grünenthal GmbH Pažeidimui atspari ir dozės atpalaidavimo nuokrypiui atspari farmacinė vaisto forma
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
JP2015521988A (ja) 2012-07-06 2015-08-03 イガレット・リミテッド 制御放出用乱用防止性医薬組成物
MX2015016254A (es) 2013-05-29 2016-04-20 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal.
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
HK1224189A1 (zh) 2013-11-26 2017-08-18 Grünenthal GmbH 通过低温研磨制备粉状药物组合物
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
WO2016170097A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
CA2998259A1 (en) 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations
DE102024107711A1 (de) * 2024-03-18 2025-09-18 Glatt Gesellschaft Mit Beschränkter Haftung Vorläufermaterial und Verwendung eines Vorläufermaterials zur Herstellung von Tabletten

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234957A (en) 1991-02-27 1993-08-10 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5223264A (en) 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
AU4219497A (en) * 1996-09-13 1998-04-02 Shionogi & Co., Ltd. Sustained-release preparation utilizing thermal change and process for the production thereof
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
JP5189242B2 (ja) * 2002-09-23 2013-04-24 アルケルメス ファーマ アイルランド リミテッド 乱用抵抗性の医薬組成物
CN100500130C (zh) * 2003-01-23 2009-06-17 株式会社太平洋 缓释制剂及其制备方法
TWI347201B (en) * 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
JP5501553B2 (ja) * 2003-04-21 2014-05-21 ユーロ−セルティーク エス.エイ. 同時押出逆作用剤粒子を含有する改変防止剤形およびその製造工程
DE10336400A1 (de) * 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20060263429A1 (en) * 2005-05-20 2006-11-23 Hengsheng Feng Compressible mixture, compressed pharmaceutical compositions, and method of preparation thereof

Similar Documents

Publication Publication Date Title
Tripathi Essentials of medical pharmacology
Borges et al. Oral films: Current status and future perspectives II—Intellectual property, technologies and market needs
DK2182902T3 (en) Compositions comprising sufentanil and triazolam for procedure sedation and analgesia using oral transmucosal dosage forms
CN110290781A (zh) 胃肠特定部位控制释放的剂型
JP2023052486A (ja) トラジピタントによる治療方法
TW522012B (en) Denaturants for sympathomimetic amine salts
TW201106990A (en) Tamper-resistant dosage form for oxidation-sensitive opioids
CA2954637A1 (en) Co-packaged drug products
JP2007502823A (ja) 接着性および生体侵食性の経粘膜薬物送達システム
Webster Update on abuse-resistant and abuse-deterrent approaches to opioid formulations
JP2016185995A5 (cg-RX-API-DMAC7.html)
JP2010518086A (ja) スフェンタニルおよびナロキソンを含む経口腔投与製剤
Gijare et al. Orodispersible films: a systematic patent review
US20170296532A1 (en) Compositions for control of drug abuse
Dhillon Hydrocodone bitartrate ER (Hysingla® ER): a review in chronic pain
CN119212681A (zh) 制备3-d打印的药物产品的方法
JP2013510841A5 (cg-RX-API-DMAC7.html)
Dhiman et al. Buccal bioadhesive delivery system of 5-fluorouracil: optimization and characterization
Darwish et al. Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects
Chwieduk et al. Fentanyl sublingual: in breakthrough pain in opioid-tolerant adults with cancer
JP2020070285A (ja) 医薬品
RS64807B1 (sr) Kombinovani lek koji obuhvata fenilefrin i paracetamol
JP2012031164A (ja) フィルム状製剤
Patil et al. Preparation and Optimization of Fast Dissolving HPMC/PVA Blended films of Loperamide Hydrochloride.
Khan et al. Abuse deterrent opioids